Luc Marengere Ph.D Managing Partner with TVM Life Science Ventures VII.

marengereDr Luc Marengere is based in Montreal, Quebec and has joined TVM Capital in spring 2012. At TVM, he is responsible for overseeing the execution of the North American investment strategy and managing certain relationships with partner Eli Lilly & Co. Prior to joining TVM, Dr. Marengere joined VG Partners in 2001 and founded the life science practice by raising over $220M for the VG Advanced Life Sciences Fund. Luc brings comprehensive knowledge of many therapeutic areas, as well as breadth of strategic expertise in operations, research and development within the biotechnology industry. Over the last ten years, he has positioned a number of companies for successful exits including CitaNeuropharma (acquired by UK-based VernalisPlc), Visualsonics (acquired by US-based Sonosite Inc.) and CytochromaInc (acquired by US-based Opko for more than $350M).

Luc has also overseen significant partnerships with large pharma and biotech in Trillium Therapeutics and Aegera Therapeutics. Prior to joining VG Partners, he was a Partner at CDP Capital – Technology Ventures where he had co-led a financing for Merix Biosciences (now Argos) with TVM Capital. He led seed investments with venture capital firm MedTech Partners where Luc oversaw trade sales for RGS Genome, Pharma-G, Tyrogene and the IPO for Medicago (recently sold to Mitsubishi-Tanabe for $357M). Dr. Marengere has served as a Director on the Board of multiple U.S. and Canadian-based life sciences companies. More recently, Luc was a Director on the Boards of Canadian-based Trillium Therapeutics Inc., Cytochroma Inc., and Aegera Therapeutics, Inc. Prior to his venture capital career, he conducted commercially-oriented research in the fields of oncology and immunology at Amgen.
Luc holds a Ph.D. in Medical Biophysics and Molecular Genetics from the University of Toronto with a specialty in protein biochemistry. Luc also graduated with an endocrinology-focused M.Sc. from Queen’s University and a degree in science from University of Ottawa (Magna Cum Laude).

Barbara J. Dalton, Ph.D. Vice President Venture Capital, Worldwide Business Development, Pfizer Inc.

Mrs Barbara DaltonDr. Dalton is Vice President of Venture Capital at Pfizer Inc. where she is responsible for Pfizer Venture Investments, managing the current private equity portfolio and advising on structured equity transactions. Dr Dalton was a founding member of EuclidSR Partners, a private venture capital firm.
She began her business career as a research scientist at SmithKline before moving to their venture capital subsidiary, S.R. One, Limited. In these roles she has managed diverse fund and company investments throughout the world. Dr Dalton is an advisor to the Dean of the Penn State Eberly College of Science, where she received her undergraduate degree, and a member of The Penn State Research Foundation Board of Directors.
She leads the Healthcare Investing Group of the New York City Investment Fund and is a former member of the Board of Directors of the Alzheimer’s Disease Research Foundation, New York Biotech Association and the National Venture Capital Association.

Dr Dalton received her PhD in Immunology and Microbiology from The Medical College of Pennsylvania.

Gary Muirhead BSc FIMLS Chief Executive Officer

Photo of Mr Gary MuirheadGary graduated in Applied Biology from Cardiff University in 1979 and then trained and was employed as a Clinical Biochemist at the University Hospital of Wales and Surrey County Hospital through to 1986. Gary then joined Roche
as a Team Leader and Senior Scientist, pharmacokinetics/Drug Metabolism. In 1993 Gary joined the Pfizer Clinical Pharmacology group in Sandwich and held positions of increasing responsibility over the subsequent 14 years. As well as managing the Clinical Pharmacologists and providing strategic leadership in the GI, GU/Sex Health and Anti-viral therapeutic areas, Gary was also the Global Clinical Pharmacology lead for a number of successful drugs including Viagra, Celsentry®, and Geodon®.

Gary also acted as Early Clinical Leader for a number of GU/Sex Health projects during this period. In 2006 Gary was appointed Sandwich Site Head for Clinical Research Operations and successfully built a group responsible for the operational delivery of exploratory development, clinical pharmacology and clinical technology clinical studies.
In June 2009 Gary was appointed to the position of Vice President, Clinical Affairs Site Head for Specialty Care in Sandwich. In this position Gary managed the clinicians, statisticians and clinical pharmacologists, ensuring the provision of quality resources to the Asset Teams. Gary is now Founder and Chief Executive Officer of Ixchelsis Ltd a Pfizer Sandwich spin-out focusing on developing drugs in Men’s Health indications.